Results 111 to 120 of about 13,687 (277)

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [PDF]

, 2015
Emerging viral diseases pose a threat to the global population as intervention strategies are mainly limited to basic containment due to the lack of efficacious and approved vaccines and antiviral drugs.
A De Milito, A De Milito, A Freiberg, A Gulland, A Marzi, A Sheraly, A Yoshimura, B Bishop, B Elander, B Salvador, D Gatherer, D Vigerust, E Fellenius, E Ooi, E Wright, F Luciani, F Perut, F Turone, G Gehring, H Feldmann, H Kibuuka, J Kouznetsova, J Lalezari, J Ledgerwood, J Long, J Nuckols, J Pallister, J Tuukkanen, K Chandran, K Gnirss, K Maitland, K Mizunashi, K Mupapa, K Müller, K Saliba, K Schornberg, L Oestereich, M Brecher, M Rutz, N Paton, N Temperton, N White, O Hart, O Moncorgé, P Jahrling, P Madrid, R Dean, R Gasparini, R Kanapathipillai, R Wool-Lewis, S Avnet, S Baize, S Chikte, S Ekins, S Mather, S Smither, T Burnouf, T Lind, T Nagata, T Shintani, V Sandrin, V Tricou, W Howard, X De Lamballerie, X Qiu, Y Li   +65 more
core   +4 more sources

Novel triplex nucleic acid lateral flow immunoassay for rapid detection of Nipah virus, Middle East respiratory syndrome coronavirus and Reston ebolavirus

Animal Diseases
We report the development of a triplex nucleic acid lateral flow immunoassay (NALFIA) for the detection of the genomes of Nipah virus (NiV), Middle East respiratory syndrome coronavirus (MERS-CoV) and Reston ebolavirus (REBOV), which are intended for ...
S. Chingtham, Diwakar Kulkarni, Sumi Sivaraman, A. Mishra, A. Pateriya, Vijendra Pal Singh, A. Raut   +6 more
semanticscholar   +1 more source

Natural History of Sudan ebolavirus to Support Medical Countermeasure Development

Vaccines, 2022
Sudan ebolavirus (SUDV) is one of four members of the Ebolavirus genus known to cause Ebola Virus Disease (EVD) in humans, which is characterized by hemorrhagic fever and a high case fatality rate.
C. Carbonnelle, Marie Moroso, D. Pannetier, Sabine Godard, S. Mély, D. Thomas, Aurélie Duthey, Ophélie Jourjon, Orianne Lacroix, Béatrice Labrosse, H. Raoul, Karen L. Osman, F. Salguero, Y. Hall, C. Sabourin, M. J. Merchlinsky, J. P. Long, Lindsay Parish, D. Wolfe   +18 more
semanticscholar   +1 more source

The ebolavirus VP24 interferon antagonist [PDF]

Virulence, 2012
Suppression during the early phases of the immune system often correlates directly with a fatal outcome for the host. The ebolaviruses, some of the most lethal viruses known, appear to cripple initial stages of the host defense network via multiple distinct paths. Two of the eight viral proteins are critical for immunosuppression. One of these proteins
Adrianna P P, Zhang, Dafna M, Abelson, Zachary A, Bornholdt, Tong, Liu, Virgil L, Woods, Erica Ollmann, Saphire   +5 more
openaire   +2 more sources

Stable SARS‐CoV‐2 antibody levels and functionality in serum and COVID‐19 convalescent plasma after long‐term storage

Vox Sanguinis, Volume 120, Issue 8, Page 784-792, August 2025.
Abstract Background and Objectives The coronavirus disease 2019 (COVID‐19) pandemic necessitated various therapeutic approaches, including convalescent plasma (CP) administration. The administration timing of COVID‐19 CP (CCP), antibody specificity and quantity were identified as crucial factors for therapeutic success.
Sandra Laner‐Plamberger, Anita Siller, Wanda Lauth, Jan Marco Kern, Lenka Baskova, Nina Held, Orkan Kartal, Harald Schennach, Eva Rohde, Christoph Grabmer   +9 more
wiley   +1 more source

Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014

Viruses, 2014
In 2014, Ebola virus (EBOV) was identified as the etiological agent of a large and still expanding outbreak of Ebola virus disease (EVD) in West Africa and a much more confined EVD outbreak in Middle Africa.
Jens H. Kuhn, Kristian G. Andersen, Sylvain Baize, Yīmíng Bào, Sina Bavari, Nicolas Berthet, Olga Blinkova, J. Rodney Brister, Anna N. Clawson, Joseph Fair, Martin Gabriel, Robert F. Garry, Stephen K. Gire, Augustine Goba, Jean-Paul Gonzalez, Stephan Günther, Christian T. Happi, Peter B. Jahrling, Jimmy Kapetshi, Gary Kobinger, Jeffrey R. Kugelman, Eric M. Leroy, Gael Darren Maganga, Placide K. Mbala, Lina M. Moses, Jean-Jacques Muyembe-Tamfum, Magassouba N'Faly, Stuart T. Nichol, Sunday A. Omilabu, Gustavo Palacios, Daniel J. Park, Janusz T. Paweska, Sheli R. Radoshitzky, Cynthia A. Rossi, Pardis C. Sabeti, John S. Schieffelin, Randal J. Schoepp, Rachel Sealfon, Robert Swanepoel, Jonathan S. Towner, Jiro Wada, Nadia Wauquier, Nathan L. Yozwiak, Pierre Formenty   +43 more
doaj   +1 more source

Rapid Sequence Identification of Potential Pathogens Using Techniques from Sparse Linear Algebra

, 2015
The decreasing costs and increasing speed and accuracy of DNA sample collection, preparation, and sequencing has rapidly produced an enormous volume of genetic data. However, fast and accurate analysis of the samples remains a bottleneck. Here we present
Chiu, Nelson, Dodson, Stephanie, Kepner, Jeremy, Ricke, Darrell O., Shcherbina, Anna   +4 more
core   +1 more source

Estimating the reproduction number of Ebola virus (EBOV) during the 2014 outbreak in West Africa [PDF]

, 2014
The 2014 Ebola virus (EBOV) outbreak in West Africa is the largest outbreak of the genus Ebolavirus to date. To better understand the spread of infection in the affected countries, it is crucial to know the number of secondary cases generated by an ...
Althaus, Christian L.
core   +2 more sources

An Interagency Collaboration to Facilitate Development of Filovirus Medical Countermeasures

Viruses, 2012
The Filovirus Animal Non-Clinical Group (FANG) is a US interdepartmental and interagency group established to support and facilitate the advanced development of filovirus Medical Countermeasures (MCM), both vaccines and therapeutics.
Edwin O. Nuzum, Nicole Kilgore
doaj   +1 more source

RIG-I activation inhibits ebolavirus replication

Virology, 2009
Hemorrhagic fever viruses are associated with rapidly progressing severe disease with high case fatality, making them of public health and biothreat importance. Effective antivirals are not available for most of the members of this diverse group of viruses. A broad spectrum strategy for antiviral development would be very advantageous. Perhaps the most
Spiropoulou, Christina F., Ranjan, Priya, Pearce, Melissa B., Sealy, Tara K., Albariño, César G., Gangappa, Shivaprakash, Fujita, Takashi, Rollin, Pierre E., Nichol, Stuart T., Ksiazek, Thomas G., Sambhara, Suryaprakash   +10 more
openaire   +2 more sources